Ask AI
ProCE Banner Activity

Clinical Advances in Immune-Engager Therapies for the Treatment of Relapsed/Refractory B-ALL

Slideset

Download this slideset to complement the online text module, “Clinical Advances in Immune-Engager Therapies for the Treatment of Relapsed/Refractory B-ALL,” featuring clear visuals and concise takeaways on emerging immune engagers, key clinical evidence, and practical considerations for patient selection, sequencing, and toxicity management.

Released: April 29, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This educational activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with ALL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply increased knowledge of clinical and molecular features that influence the selection and sequencing of immune-targeted therapies in acute lymphoblastic leukemia (ALL)

  • Integrate emerging evidence from clinical trials, recent approvals, and updated guideline recommendations for bispecific T-cell engagers and CAR T-cell therapies into the management of patients with ALL

  • Develop evidence-based strategies to proactively recognize and manage adverse events associated with immune-targeted agents, supporting early intervention and sustained patient benefit in ALL care